Latest news

• AZ forecasts growth in 2021 after revenues surge in Q4

  Shares in AstraZeneca (AZ) were up by over 2% in morning trading after fourth quarter (Q4) sales beat expectations, with strong growth now forecasted for 2021. ... AZ added that this most recent quarter was the first ‘for many years’ in which product

• Roche’s diagnostic business sales offer a bright spot in Q4

  Elsewhere in Roche’s Q4 results, the company’s pharmaceuticals division took a hit, slipping 2% in 2020 due to the continuing impact from biosimilars on key products, including its cancer ... However, group sales climbed by 1% overall at constant

• Sanofi reports a profit in Q4 as Dupixent sales climb

  Shares in French pharma company Sanofi climbed around 3% in premarket activity after it posted a profit in its 2020 fourth quarter (Q4) results, following a net loss in the same ... For the full year, Dupixent generated sales of 3.5bn, again making gains

• Gilead’s COVID-19 drug Veklury brought in almost $2bn in Q4

  In Q4 2020, Veklury brought over $1.9bn, while for the full year the antiviral drug produced sales of $2.8bn. ... However, aside from Veklury, there were some other product sale increases among the Q4 results, including growth for Gilead’s cell

• Pfizer aims for $15bn in 2021 COVID-19 vaccine sales

  Current estimate is based on already agreed contracts. Pfizer has forecast major sales expectations for its BioNTech-partnered COVID-19 vaccine, BNT162b2, in its fourth quarter results – aiming for approximately $15bn ... For Pfizer’s total vaccine